# Benralizumab Pregnancy Exposure Study

> **NCT03794999** · — · TERMINATED · sponsor: **AstraZeneca** · enrollment: 299 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Benralizumab-exposure
- **DRUG:** Exposure to other asthma medications

## Key facts

- **NCT ID:** NCT03794999
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-20
- **Primary completion:** 2023-12-29
- **Final completion:** 2023-12-29
- **Target enrollment:** 299 (ACTUAL)
- **Why stopped:** The decision to terminate the Fasenra pregnancy study and cancel the commitment to conduct additional pregnancy-related pharmacovigilance activities was made by the EMA following MAH's failed attempts to address patient recruitment challenges.
- **Last updated:** 2024-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794999, "Benralizumab Pregnancy Exposure Study". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03794999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*